Deutsche Bank Adjusts Alkermes Price Target to $42 From $43, Maintains Buy Rating
Deutsche Bank has adjusted its price target for Alkermes plc (ALKS) from $43 to $42, while reiterating a Buy rating on the stock. This update reflects a minor change in the bank's valuation for the biopharmaceutical company. Alkermes recently completed the acquisition of Avadel Pharmaceuticals plc, expanding its presence in the sleep medicine market.
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?
Alkermes (ALKS) is positioned for another earnings beat in its upcoming quarterly report, thanks to a strong history of surpassing analyst estimates and a favorable Zacks Earnings ESP of +1.54%. The company's average surprise in the last two quarters was 21.75%, and with a Zacks Rank #1 (Strong Buy), there's a strong indication of a positive surprise. Investors are advised to watch for the earnings release on February 25, 2026.
Alkermes plc (ALKS) Stock Analysis: Strong Buy Ratings and a Promising 32% Upside Potential
Alkermes plc (NASDAQ: ALKS) is highlighted as a compelling investment due to strong buy ratings and a projected 32.12% upside potential. The biopharmaceutical company, with a market cap of $5.48 billion, focuses on proprietary products for neurological disorders and mental health, demonstrating solid financial health with 4.20% revenue growth and a 22.35% return on equity. Analysts have an average target price of $43.81, driven by its innovative portfolio and strategic collaborations.
Ireland's Alkermes plc buys Avadel Pharmaceuticals plc
Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc for $2.3 billion in cash and debt, incorporating Avadel's FDA-approved narcolepsy drug, LUMRYZ, into its commercial portfolio. This strategic move expands Alkermes' presence in sleep medicine, enhances its pipeline, and is expected to be financially accretive in 2026. The acquisition was financed through a combination of Alkermes' cash reserves and $1.525 billion in term loans, with financial expectations for the combined entity to be released on February 25, 2026.
Ireland's Alkermes plc buys Avadel Pharmaceuticals plc
Alkermes plc has completed its $2.3 billion acquisition of Avadel Pharmaceuticals plc, significantly expanding its commercial portfolio with the FDA-approved narcolepsy drug LUMRYZ. This strategic move strengthens Alkermes' presence in sleep medicine, enhances its commercial capabilities, and is expected to be accretive in 2026. The acquisition also includes Avadel's late-stage pipeline candidate, valiloxybate, and was financed through a combination of cash and term loans.
Public Sector Pension Investment Board Has $21.32 Million Stock Holdings in Alkermes plc $ALKS
The Public Sector Pension Investment Board increased its stake in Alkermes plc by 11.6% in the third quarter, now owning 710,700 shares valued at $21.32 million. Institutional investors collectively own 95.21% of Alkermes stock. Analysts have a "Moderate Buy" consensus rating for Alkermes with an average price target of $44.69, while company insiders have sold approximately $5.03 million worth of shares recently.
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss
Agios Pharmaceuticals reported a narrower-than-expected loss of $1.85 per share in Q4 2025, beating the Zacks Consensus Estimate. Total revenues reached $20 million, significantly exceeding expectations, driven by strong product revenues from Pyrukynd. The company launched its new drug Aqvesme in the U.S. and provided updates on its pipeline, including mitapivat for sickle cell disease.
Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market
Alkermes PLC has announced the completion of its acquisition of Avadel Pharmaceuticals PLC. This strategic move is expected to accelerate Alkermes' entry into the sleep medicine market. The news was reported by Refinitiv.
Alkermes, Inc. , Alkermes, Inc and Alkermes Finance LLC Enters into Credit Agreement
Alkermes plc, along with Alkermes, Inc. and Alkermes Finance LLC, has entered into a credit agreement providing for two senior secured term loan facilities totaling $1.525 billion. These facilities, a $750 million TLA Facility and a $775 million TLB Facility, mature in February 2031 and August 2031, respectively. The company fully borrowed the aggregate amount on the closing date, with interest rates based on the Term SOFR Rate or Alternate Base Rate plus a Secured Net Leverage Ratio-based margin.
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
Alkermes plc has successfully completed its acquisition of Avadel Pharmaceuticals plc, integrating Avadel's FDA-approved narcolepsy treatment, LUMRYZ®, into its commercial portfolio. This strategic move is expected to accelerate Alkermes' entry into the sleep medicine market and bolster its revenue growth profile. The transaction, financed by cash and term loans, is anticipated to be accretive in 2026, with Alkermes planning to provide detailed financial expectations for the combined entity on February 25, 2026.
Alkermes Completes Avadel Acquisition, Expands Sleep Medicine Portfolio
Alkermes has completed its all-cash acquisition of Avadel Pharmaceuticals, adding the FDA-approved narcolepsy treatment LUMRYZ and an early-stage candidate to its portfolio. The acquisition, financed by cash and senior secured term loans totaling $2.275 billion, is expected to be accretive in 2026 and enhances Alkermes' presence in the sleep medicine and rare disease markets. This strategic move aims to broaden Alkermes' revenue base and position it as a more diversified CNS player.
Alkermes (Nasdaq: ALKS) closes Avadel acquisition, adds LUMRYZ and $1.5B loans
Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, gaining the FDA-approved narcolepsy drug LUMRYZ and a specialized commercial team for sleep medicine. The deal involves an all-cash payment of $21.00 per share plus a contingent value right for Avadel shareholders, financed by $750 million from Alkermes' cash and $1.525 billion in new senior secured term loans. This strategic move aims to enhance Alkermes' revenue growth, expand its neuroscience portfolio, and is expected to be accretive in 2026.
Understanding the Setup: (ALKS) and Scalable Risk
This article provides an in-depth analysis of Alkermes Plc (ALKS), highlighting strong near and mid-term sentiment but elevated downside risk in the long term. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The report also details multi-timeframe signal analysis, including support and resistance levels.
Alkermes (Nasdaq:ALKS) - Stock Analysis
This Simply Wall St report provides a stock analysis of Alkermes (Nasdaq:ALKS), a biopharmaceutical company specializing in neurological disorders. It evaluates the company's valuation, future growth prospects, past performance, financial health, dividend policy, management, and ownership, noting that the stock is trading significantly below its estimated fair value. The report highlights potential growth drivers, such as the efficacy of Alixorexton and market expansion opportunities, alongside risks like reliance on a narrow product range and high R&D spending.
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation on Wednesday, February 25, 2026, at 8:00 a.m. ET (1:00 p.m. GMT) to discuss its fourth quarter and year-end 2025 financial results. Management will also provide 2026 financial expectations and a company update. The webcast and accompanying slides will be available on the Investors section of Alkermes' website.
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, integrating Avadel's FDA-approved narcolepsy drug, LUMRYZ, into its commercial portfolio. This strategic acquisition accelerates Alkermes' entry into the sleep medicine market, strengthens its commercial infrastructure, and is expected to be accretive to revenue growth in 2026. The deal positions Alkermes for expanded innovation in treating sleep and neurological disorders.
Irish High Court sanctions Avadel Pharmaceuticals acquisition by Alkermes
The Irish High Court has sanctioned the acquisition of Avadel Pharmaceuticals (AVDL) by Alkermes (ALKS) without modification. The transaction is pending the delivery of the Court Order to the Registrar of Companies, expected on February 12, after which the scheme is anticipated to take effect. Trading of Avadel Shares on Nasdaq is expected to halt on February 11, marking the final day of trading.
Alkermes plc (NASDAQ:ALKS) Given Average Recommendation of "Moderate Buy" by Brokerages
Alkermes plc (NASDAQ:ALKS) has received a consensus "Moderate Buy" rating from sixteen brokerages, with an average 1-year target price of $44.69, suggesting a 28% upside. Despite significant institutional ownership (95.21%), company insiders have recently sold 148,148 shares valued at approximately $5.03 million. The stock is currently trading near its 1-year high and has a market capitalization of $5.76 billion.
Allianz Asset Management GmbH Acquires 511,702 Shares of Alkermes plc $ALKS
Allianz Asset Management GmbH significantly increased its stake in Alkermes plc (NASDAQ:ALKS) by 3,908.2% in the third quarter, acquiring 511,702 additional shares to own a total of 524,795 shares valued at approximately $15.74 million. Other institutional investors like Norges Bank and BNP Paribas also boosted their holdings, with institutional investors now owning 95.21% of the company. Wall Street analysts maintain a "Moderate Buy" rating for Alkermes, with a consensus price target of $44.69 against a recent trading price of $34.91.
KOD Stock Up 24% in 3 Months: Here's What You Need to Know
Kodiak Sciences' (KOD) shares have risen 24% over the past three months due to strong momentum in its late-stage pipeline programs, including tarcocimab, KSI-501, and KSI-101 for various retinal indications. The company's robust funding from a recent equity offering has also bolstered its balance sheet, extending its cash runway. Despite carrying a Zacks Rank #4 (Sell), investor confidence is high due to forthcoming clinical trial data and potential regulatory filings.
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
Bristol-Myers Squibb (BMY) reported better-than-expected fourth-quarter 2025 adjusted earnings per share of $1.26 and total revenues of $12.5 billion, leading to a stock increase. The company's Growth Portfolio, featuring drugs like Opdivo and Reblozyl, drove a 16% year-over-year revenue increase in this segment. Despite strong performance in these new products, the Legacy Portfolio saw a 15% decline due to generic competition, but the company issued an optimistic 2026 revenue guidance of $46-$47.5 billion.
Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 9,000 Shares
Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson recently sold 9,000 shares of the company's stock for a total of $305,370. This transaction reduced his stake by 13.49% to 57,740 shares. The company's stock traded up on the day of the report, and institutional investors hold a significant portion of shares, while analysts maintain a "Moderate Buy" consensus rating with a $44.69 price target.
Alkermes (NASDAQ:ALKS) Director Sells $2,115,684.00 in Stock
Alkermes director Shane Cooke sold 61,200 shares of the company's stock on February 2nd for over $2.1 million, reducing his stake by 37.10%. Following the sale, Cooke directly owns 103,744 shares. The biotech company (NASDAQ: ALKS) has seen strong institutional ownership and a "Moderate Buy" consensus rating from analysts with an average price target of $44.69.
Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome
Ultragenyx Pharmaceutical has resubmitted its Biologics License Application (BLA) for UX111, an AAV gene therapy for Sanfilippo syndrome type A (MPS IIIA), to the FDA. The resubmission addresses previous manufacturing and facility-related concerns raised in a Complete Response Letter and includes additional long-term clinical data. Ultragenyx anticipates a six-month review period with a target action date in the third quarter of 2026, hoping to bring the first approved treatment for this rare, fatal lysosomal storage disorder to market.
The Technical Signals Behind (ALKS) That Institutions Follow
This article analyzes Alkermes Plc (NASDAQ: ALKS), highlighting that if near and mid-term strong sentiment holds, it could extend to the long term, though with elevated downside risk due to a lack of long-term support signals. It details three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with specific entry, target, and stop loss points. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for the stock.
Are options traders betting on a big move in Alkermes stock?
This article discusses whether options traders are anticipating a significant price movement in Alkermes (ALKS) stock. It likely analyzes options activity, such as unusual call or put volumes, implied volatility, and open interest, to gauge market sentiment regarding the stock's future direction.
Alkermes plc $ALKS Shares Sold by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd significantly reduced its stake in Alkermes plc by selling 85,366 shares, now holding 53,067 shares valued at approximately $1.59 million. Despite this, institutional ownership remains high at around 95.21%, with several other large investors increasing or initiating positions. Analysts maintain a "Moderate Buy" consensus with a target price of $44.69, and recent earnings surpassed estimates.
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug
Summit Therapeutics (SMMT) announced that the FDA has accepted its Biologics License Application (BLA) for ivonescimab plus chemotherapy for EGFR-mutated non-small cell lung cancer (NSCLC) patients. The FDA has set a target action date of November 14, 2026. This application is based on data from the phase III HARMONi study, which met its primary endpoint for progression-free survival.
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
Teva Pharmaceutical Industries (TEVA) reported strong fourth-quarter 2025 results, beating Zacks Consensus Estimates for both earnings and revenue. The company's performance was primarily driven by a significant milestone payment from Sanofi and robust sales growth from its branded drugs, Austedo, Ajovy, and Uzedy, despite some declines in international markets. TEVA also provided a positive outlook for 2026, anticipating continued growth in its innovative portfolio.
Are Options Traders Betting on a Big Move in Alkermes Stock?
Options traders are showing significant interest in Alkermes (ALKS) stock, indicated by the high implied volatility of its Feb 20, 2026 $37 Put options. This suggests expectations of a notable price movement due to upcoming events or current market sentiment. Despite a recent downward revision in earnings estimates by one analyst, Zacks maintains a "Strong Buy" rating for Alkermes, implying that the high implied volatility could present a trading opportunity, particularly for those looking to sell premium.
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
Halozyme Therapeutics (HALO) shares climbed almost 4% after releasing strong preliminary full-year 2025 results that exceeded expectations and raising its sales and EPS guidance for 2026. The company's revenues are primarily driven by product sales, royalty payments from major pharmaceutical companies for its Enhanze technology, and revenues from collaborative agreements. HALO also broadened its technology base through recent acquisitions, projecting continued growth and an increased number of partner programs and licensing agreements.
Alkermes stock price target raised to $47 from $46 at UBS on Avadel deal
UBS has increased its price target for Alkermes (NASDAQ:ALKS) to $47.00 from $46.00, maintaining a Buy rating. This adjustment follows UBS's updated financial model, which accounts for Alkermes' pending acquisition of Avadel Pharmaceuticals, expected to close in Q1 2026. The acquisition is anticipated to boost EBITDA growth and strengthen Alkermes' Sleep franchise, alongside potential clinical catalysts from Lumryz and alixorexton IH trial results.
Alkermes stock price target raised to $47 from $46 at UBS on Avadel deal
UBS has increased its price target for Alkermes (NASDAQ:ALKS) to $47 from $46, while maintaining a Buy rating, due to the anticipated acquisition of Avadel Pharmaceuticals. This increased target reflects an updated pro-forma model and the expected close of the Avadel deal in Q1 2026, which is predicted to boost Alkermes' EBITDA and Sleep franchise. The company also recently received Breakthrough Therapy designation for alixorexton and increased its offer for Avadel to $21.00 per share plus a contingent value right.
Alkermes stock price target raised to $47 from $46 at UBS on Avadel deal
UBS has increased its price target for Alkermes (NASDAQ:ALKS) to $47 from $46, maintaining a Buy rating, following the company's pending acquisition of Avadel Pharmaceuticals. The acquisition is expected to close in Q1 2026 and contribute to EBITDA growth, particularly in its Sleep franchise, and benefit from clinical catalysts. This adjustment reflects an updated financial model and Alkermes' strong financial position, with the company also having recently received Breakthrough Therapy designation for alixorexton and increased its offer for Avadel to $21.00 per share plus a contingent value right.
Jim Cramer on Alkermes: "I Think It's a Hold, Maybe a Weak One"
Jim Cramer has a dim view of Alkermes (NASDAQ: ALKS), rating it as a "hold, maybe a weak one." This comes despite the company announcing that the FDA granted Breakthrough Therapy designation for its narcolepsy type 1 treatment, alixorexton, which showed positive phase 1 and 2 results. Cramer's skepticism is interesting in light of the promising clinical data.
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
ImmunityBio's stock surged 17.4% after the company met with the FDA to discuss the regulatory path for resubmitting its sBLA for Anktiva, aimed at treating BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors. The company plans to submit the requested additional analyses within a month, building on positive long-term data from its QUILT-3.032 study which showed durable disease control and bladder-sparing benefits. If approved, Anktiva would be the first immunotherapy for this condition, addressing a significant unmet medical need.
Jim Cramer on Alkermes: “I Think It’s a Hold, Maybe a Weak One”
Jim Cramer discussed Alkermes (NASDAQ: ALKS), stating he considers it a "hold" or "weak hold" due to its performance, despite recent positive news. Alkermes announced that its alixorexton therapy received FDA Breakthrough Therapy designation for narcolepsy type 1, showing promising results in early trials. The company plans to advance alixorexton into Phase 3 development later in the quarter.
Jim Cramer on Alkermes: “I Think It’s a Hold, Maybe a Weak One”
Jim Cramer has characterized Alkermes plc (NASDAQ: ALKS) as a "hold, maybe a weak one" despite the biopharmaceutical company's recent positive developments. Alkermes announced that its alixorexton therapy for narcolepsy type 1 received Breakthrough Therapy designation from the FDA, following positive phase 1 and 2 study results. The company plans to advance alixorexton into phase 3 development, with the potential to offer a new standard of care for narcolepsy type 1.
Jim Cramer on Alkermes: “I Think It’s a Hold, Maybe a Weak One”
Jim Cramer has a "hold, maybe a weak one" rating on Alkermes (ALKS), noting that the stock hasn't performed as well as expected. Alkermes recently received Breakthrough Therapy designation from the FDA for its alixorexton therapy for narcolepsy type 1, showing promising phase 1 and 2 trial results. The company plans to advance alixorexton into phase 3 development, with the potential to offer a new standard of care for narcolepsy type 1.
Campbell & CO Investment Adviser LLC Has $741,000 Position in Alkermes plc $ALKS
Campbell & CO Investment Adviser LLC significantly reduced its stake in Alkermes plc, selling over 31,000 shares, yet institutional ownership of the company remains very high at 95.21%. Despite some insider selling, Alkermes exceeded quarterly earnings expectations and provided strong FY2025 guidance, resulting in a consensus "Moderate Buy" rating from analysts with an average price target of $44.69. The stock is currently trading around $31.75.
Precision Trading with Alkermes Plc (ALKS) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Alkermes Plc (ALKS), highlighting strong sentiment and resistance testing. It outlines specific trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, alongside multi-timeframe signal analysis. The report emphasizes the potential for an exceptional risk-reward short setup and offers access to real-time AI-generated signals and institutional-grade analysis.
Avadel Sets Court Date for Alkermes Acquisition Scheme
The Irish High Court has scheduled a sanction hearing for February 10, 2026, to consider Alkermes plc's acquisition of Avadel Pharmaceuticals. This acquisition, which began its offer period on October 22, 2025, is expected to finalize shortly after the court's approval. Shareholders holding 1% or more of Avadel's securities are subject to Irish Takeover Rules disclosure obligations.
Avadel (NASDAQ: AVDL) moves Alkermes acquisition forward with Irish court hearing date
Avadel Pharmaceuticals (NASDAQ: AVDL) has announced that the High Court of Ireland has scheduled a sanction hearing for February 10, 2026, regarding Alkermes plc's acquisition of Avadel. This hearing is a crucial step towards finalizing the acquisition, which is expected to close shortly after the court issues its sanctioning order. Interested parties must notify Avadel's solicitors and file supporting documents by February 5, 2026.
Alkermes (ALKS) Is Up 6.8% After FDA Breakthrough Tag for Narcolepsy Drug Candidate Alixorexton - What's Changed
Alkermes received FDA Breakthrough Therapy designation for alixorexton, an oral orexin 2 receptor agonist for narcolepsy type 1, following positive data from the Vibrance-1 trial. This designation could accelerate the drug's development and reshape Alkermes' investment outlook, though regulatory risks and increased R&D spending remain factors. The company's future projections include $1.4 billion revenue by 2028, with current analysis suggesting a fair value of $43.81, a 39% upside.
Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton, Potentially Accelerating Development
Alkermes received FDA Breakthrough Therapy Designation for its drug alixorexton, based on positive data from the Vibrance-1 study, which could improve treatments for narcolepsy and enhance Alkermes' competitive stance in the sleep disorder market. This designation is expected to accelerate development across various sleep disorders, potentially diversifying revenue and bolstering investor confidence. While Alkermes projects a 1.3% annual revenue decline by 2028, this FDA recognition could significantly alter market perceptions of its long-term financial prospects and impact its stock price.
Alkermes (ALKS) Is Up 6.6% After FDA Breakthrough Tag for Narcolepsy Drug Alixorexton
Alkermes plc's stock rose 6.6% after the FDA granted Breakthrough Therapy designation to its narcolepsy drug, alixorexton, based on positive phase 1 and 2 trial data. This designation could accelerate development and reshape the company's long-term orexin pipeline. While the breakthrough is positive, the company still faces risks related to funding and regulatory approvals for its neuroscience portfolio.
Alkermes (ALKS) Is Up 6.6% After FDA Breakthrough Tag for Narcolepsy Drug Alixorexton
Alkermes received FDA Breakthrough Therapy designation for alixorexton, its narcolepsy drug, based on positive Phase 1 and 2 trial data, including the Vibrance-1 study. This designation could accelerate development of its orexin agonist franchise and potentially improve existing narcolepsy treatments. The company's future growth hinges on its neuroscience portfolio funding the orexin agonist program and successful late-stage data.
ALKS: RBC Capital Raises Price Target to $47, Maintains 'Outperf
RBC Capital has raised its price target for Alkermes (ALKS) to $47.00 from $45.00, while maintaining an 'Outperform' rating. This adjustment reflects a 4.44% increase in the price target by analyst Leonid Timashev. Alkermes, a biotechnology company focused on unmet medical needs, has an average analyst target price of $43.40, suggesting a potential upside of 39.59% from its current price of $31.09, though GuruFocus's GF Value estimates a downside.
Avadel Pharmaceuticals shareholders approve $2.37B takeover bid
Avadel Pharmaceuticals PLC shareholders have approved a $2.37 billion takeover bid from Alkermes. The Ireland-based company, which has its U.S. operations in Chesterfield, received this approval, though the future of its local operations remains uncertain. The acquisition values the company at $2.37 billion.
Apellis Stock Crashes 23% in a Week: Here's What You Should Know
Apellis Pharmaceuticals (APLS) stock dropped 22.6% in the past week following its preliminary Q4 2025 revenue report, which failed to impress investors, particularly regarding Syfovre sales. Despite Syfovre being a market leader, its sales declined year-over-year, while Empaveli sales increased due to a new indication approval. The company also provided pipeline updates for Empaveli and APL-3007, and expects current cash to fund operations to profitability.
